Home Leukocyte Activation Markers in Clinical Practice
Article
Licensed
Unlicensed Requires Authentication

Leukocyte Activation Markers in Clinical Practice

  • José Antonio Viedma Contreras
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 37 Issue 6

Abstract

The response against tissue injury and infection begins with the early activation of molecular and cellular elements of the inflammatory and immune response. Severe tissue injury, necrosis, and infection induce imbalanced inflammation associated with leukocyte over-stimulation and excessive or dysregulated release of cellular mediators. Clinical and experimental studies have shown that these mediators are directly related to progressive post-injury complications. Persistent increased levels of pro-inflammatory mediators produce tissue injury. Excessive production and activity of anti-inflammatory mediators cause anergy and/or immune dysfunction with increased susceptibility to infection. Leukocyte activation is assessed by cell surface phenotype expression, cellular mediators determination, or by measuring functional responses using isolated cells. Potential routine clinical uses are: evaluation of severity and prognosis in critically ill patients, immunomonitoring of sepsis, and detection of tissue injury, necrosis, and infection. In practice, the determination of cellular activation markers is restricted by a limited number of automated methods and by the cost of reagents. The availability of flow cytometry and immunoassay automated systems can contribute to a wider use in pracice. Here we review the immunopathophysiology of polymorphonuclear neutrophil, monocyte, macrophage, and lymphocyte activation in response to tissue injury and infection. In addition, laboratory methods for their determination, and clinical applications in practice, are discussed.

:
Published Online: 2005-06-01
Published in Print: 1999-06-01

Copyright © 1999 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Meetings and Awards
  2. Are Cardiac Troponins the Myocardial Markers for the New Millenium?
  3. Leukocyte Activation Markers in Clinical Practice
  4. Hepatitis C Virus-Specific DNA Sequences in Human DNA: Differentiation by Means of Restriction Enzyme Analysis at the DNA Level of Healthy, Anti-HCV-Negative Individuals
  5. Characterization of Monoclonal Antibodies to Human Protein 1/Clara Cell 10 Kilodalton Protein
  6. Rapid Analysis of Parathion in Biological Samples Using Headspace Solid-Phase Micro-Extraction (HS-SPME) and Gas Chromatography/Mass Spectrometry (GC/MS)
  7. Semi-Automated Rapid Isoelectric Focusing of Apolipoproteins C from Human Plasma Using PhastSystem™ and Immunofixation
  8. The c-erbB-2 Oncogene Amplification by Competitive PCR in Aneuploid Cell Clones Flow Sorted from Breast Cancer Samples
  9. The Index of Individuality Is Often a Misinterpreted Quantity Characteristic
  10. Assessment of Package Inserts for Diagnostic Kits
  11. External Quality Assessment in Clinical Chemistry: Review of the Situation in Croatia with Particular Reference to Equipment
  12. Point-of-Care Testing: the Views of the Working Group of the Dutch Association of Clinical Chemistry
  13. Preliminary Evaluation of the New Hematology Analyzer COULTER® GEN•S™ in a University Hospital
  14. Use of Biochemical Markers in Acute Coronary Syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage
  15. Oxidative Stress in Skeletal Muscle. A.E. Rezuick, L. Packer, C.K. Sen. J.O. Hollosey and M.J. Jackson, editors
  16. Handbook of Lipoprotein Testing. N. Rifai, C.G. Warnick and M.H. Dominiczak, editors
  17. Erratum: Matthias Oberhoffer, Heinz Vogelsang, Stefan Rußwurm, Thomas Hartung and Konrad Reinhart. Outcome Prediction by Traditional and New Markers of Inflammation in Patients with Sepsis
Downloaded on 9.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.1999.096/html
Scroll to top button